Treatment with microRNAs in hepatocellular carcinoma

Introduction: Hepatocellular carcinoma (HCC), also called malignant hepatoma, is the most usual type of liver cancer. Many studies have investigated expression signature of microRNAs (miRNA) in HCC patients, mainly patients who are treated with contractual therapy of this disease.Description: Using miRNAs as prognostic or diagnostic biomarkers by the molecular methods in different cancers has been widely used studied. The expression types of miRNAs are dysregulated in different cancers. Increasing evidence proving that miRNAs can act as an oncogene or a tumor suppressor. Treatment with miRNAs mostly depends on nucleic acid-based strategies. The target of these strategies is to restore the normal function of miRNAs.Discussion and Conclusion: Most current studies have concentrated on use of miRNAs as therapeutic method and significant progress has been made in this field which is promising. It becomes manifest that HCC is appearing as a model for transmission from contractual to new Treatment with microRNAs.